This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Resolvine ER

Kato Pharmaceuticals, Inc.

Drug Names(s): Resolvine ER

Description: Resolvine ER is a novel therapeutic with an undisclosed mechanism of action.

Deal Structure: Kato Pharmaceuticals and Lee's Pharmaceutical
In October 2016, Kato Pharmaceuticals and Lee's Pharmaceutical jointly announced that Lees Pharm has licensed, through its wholly-owned subsidiary, Zhaoke Pharmaceutical (HK), Katos Resolvine ER. Under the terms of the agreement, Lee's Pharm received exclusive rights to develop and commercialize Resolvine ER in Greater China (including the People's Republic of China, Hong Kong, Macau and Taiwan) and South East Asia, with an option to add South Korea to the contractual territory. In exchange, Kato will receive an upfront licensing fee, potential future milestone payments and tiered royalties on future net sales. Lees Pharm will pay for the development, approval and commercialization of Resolvine ER in its licensed territories and will focus initially on clinical development of Resolvine ER for the treatment of diabetic retinopathy. Additionally, Lees Pharm has also made an equity investment in Kato through Lees Healthcare...See full deal structure in Biomedtracker

Partners: Lee's Pharmaceutical Holdings Limited


Resolvine ER News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug